Sanofi SASAN
▲ PositiveCapitalrelevance
High dividend yield and buybacks, strong sales growth, and attractive valuation.
Impact on stocks 1
Health Care
Sanofi SASanofi Offers 5.6% Dividend Yield and Promising Growth Pipeline
Earnings
Sanofi, the French pharmaceutical company, offers a 5.6% dividend yield and a total shareholder yield approaching 11% when including stock buybacks. Its top drug Dupixent saw first-quarter sales grow 31% year over year, driving overall sales up 13.6%. The stock trades at a forward price-to-earnings ratio of 9, below its five-year average of 11, and has fallen nearly 15% over the past year. Sanofi also reported five regulatory approvals in immunology during the quarter and has a pipeline of drugs in development that could offset future patent expirations.
Sanofi SAHigh dividend yield and buybacks, strong sales growth, and attractive valuation.